Paladin gains FDA approval for leishmaniasis drug

03/20/2014 | Reuters

Canadian pharmaceutical firm Paladin Labs received federal approval for its Impavido drug to address leishmaniasis, a parasitic disease transmitted via sand fly bites that is usually acquired when traveling abroad. The drug is to be used in patients 12 and older.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA